Arkolith/Insider Trading/OLMA/Form 4

Clark Ian T

DirectorOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Dec 23, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.9M
Net Open-Market Flow
-$7.9M
Transactions
11
7 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 19, 2025Option exercise(M)210K$4.41$925K210K
Dec 19, 2025Option exercise(M)22K$3.61$78K231K
Dec 19, 2025Option exercise(M)22K$7.84$169K253K
Dec 19, 2025Option exercise(M)12K$4.08$49K265K
Dec 19, 2025Sell(S)30K$28.83$862K235K
Dec 19, 2025Sell(S)193K$29.71$5.7M42K
Dec 19, 2025Sell(S)42K$30.48$1.3M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 19, 2025Option exercise(M)210K—$00
Dec 19, 2025Option exercise(M)22K—$00
Dec 19, 2025Option exercise(M)22K—$00
Dec 19, 2025Option exercise(M)12K—$012K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001336504-25-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML